Portuguese national health service has decided to offer Spinraza treatment.
According to Portuguese media, a preliminary agreement was reached last week and all the details are expected to be finalised by summer. It is understood that the treatment will be provided irrespective of SMA type.
Experts quoted by the media point out that evidence of the drug’s efficacy in adults is scarce, even as they suggest that Spinraza treatment should at least stop functional decline in adults.
Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.
SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…
This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.
